Rifampicin and moxifloxacin for tuberculous meningitis - Authors' reply

The Lancet Infectious Diseases

Volumn 13, Issue 7, 2013, Pages 570-

  Ruslami, Rovina ^a   Ganiem, A Rizal ^a   Aarnoutse, Rob E ^b   Van Crevel, Reinout ^b  

^a PADJADJARAN UNIVERSITY   (Indonesia)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

BACTERIAL MENINGITIS; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL; DRUG BLOOD LEVEL; HUMAN; LETTER; LUNG TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; TREATMENT OUTCOME; TUBERCULOUS MENINGITIS;

ANTITUBERCULAR AGENTS; AZA COMPOUNDS; FEMALE; HUMANS; MALE; QUINOLINES; RIFAMPIN; TUBERCULOSIS, MENINGEAL;

EID: 84879754866     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(13)70156-7     Document Type: Letter

References (5)

1. Mitchison DA, Chang KC Experimental models of tuberculosis: can we trust the mouse?. Am J Respir Crit Care Med 2009, 180:201-202.
2. Rustomjee R, Lienhardt C, Kanyok T, et al. Gatifloxacin for TB (OFLOTUB) Study Team. A phase II study of the sterilizing activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008, 12:128-138.
3. Conde MB, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009, 373:1183-1189.
4. Burman WJ, Goldberg S, Johnson JL, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006, 174:331-338.
5. Alffenaar JW, van Altena R, Bökkerink HJ, Luijckx GJ, et al. Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis. Clin Infect Dis 2009, 49:1080-1082.